# ProteLight Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protelight-pharma

- Industry: Pharmaceuticals
- Headquarters: Wuxi, China
- Website: www.protelight.com
- Latest round: Series D (Jan 4, 2026)
- Investors on record: 5

## About

Based in Jiangsu, China and established in 2009, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., trading as ProteLight Pharma is a biomedical technology company focusing on R&D and production of polypeptide and chemical drugs. In January 2025, ProteLight Pharma raised Series D funding from new investor Guangzhou Cherami Sun Tour Equity Investment Management, Qingdao Guoxin Venture and Efung Capital.
The company focuses on innovative drug development, with a pipeline of first-in-class peptide drugs targeting anti-infection and anti-cancer indications. It holds numerous patents, including PCT international patents and US/EU invention patents.
Revenue is generated from sales of innovative peptide drugs, licensing intellectual property, and providing R&D services for pharmaceutical partners.

## Funding rounds

- Series D, Jan 4, 2026 — Efung Capital, Qingdao Guoxin Venture, Guangzhou Cherami Sun Tour Equity Investment Management
- Series B, Dec 9, 2016 — Hangzhou Binjiang Investment Holding, Yinxinggu Capital

## Investors

- Hangzhou Binjiang Investment Holding — Series B
- Yinxinggu Capital (https://capitalatlas.ai/funds/yinxinggu-capital) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series D
- Qingdao Guoxin Venture — Series D
- Guangzhou Cherami Sun Tour Equity Investment Management — Series D